Aequus sees fiscal 2020 revenue rise by 59%, driven by strong sales of Vistitan and Tacrolimus
For the year ended December 31, 2020, it reported revenue of $2.6 million, compared to $1.6 million during the year ended December 31, 2019 COO Grant Larsen said that Vistitan revenue at +15% and Tacrolimus at +49% showed strong consistent growth
Aequus Pharmaceuticals Inc. (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) posted fiscal 2020 results that saw its annual revenue jump 59% year-over-year on the back of strong sales led by PRVistitan and Tacrolimus eye treatments.
For the year ended December 31, 2020, the Vancouver, British Columbia-based specialty pharmaceutical company reported its highest annual revenue to date of $2.6 million, up 59%, compared to $1.6 million during the year ended December 31, 2019. The company chalked the bump in revenue to higher sales.